Cost-effectiveness of trastuzumab deruxtecan in previously treated human epidermal growth factor receptor 2-low metastatic breast cancer.
Jiangping YangJiaqi HanNi ZengXi YanPublished in: Therapeutic advances in medical oncology (2023)
T-DXd provides significant health benefit for patients with HER2-low mBC compared with chemotherapy but is unlikely to be cost-effective in the United States.
Keyphrases